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hyperplasia lined by enlarged endothelial cells, inflamma-
tory infiltrate with lymphocytes and eosinophils.
(Hematoxylin-eosin stain; original magnification: 3200.)
Abbreviation used:
ALHE: angiolymphoid hyperplasia with
eosinophiliaINTRODUCTION
Angiolymphoid hyperplasia with eosinophilia
(ALHE) is an uncommon, benign disorder that
presents as solitary or multiple papulonodules,
located predominantly in the head and neck region.
The pathogenesis of ALHE remains controversial. It
has occurred following various forms of trauma or
infection. The disorder is commonly regarded as an
angioproliferative process accompanied by an
inflammatory infiltrate that is thought to be a reactive
component. ALHE may represent a T-cell lympho-
proliferative disorder of a benign or low-grade
malignant nature.1 Other reported cases have shown
damaged arteries and veins at the base of the lesion,
suggesting that an underlying arteriovenous
malformation may play a role in the pathogenesis.2
Additionally, some evidence suggests that ALHEmay
be related to traumatic pseudoaneurysm, supporting
a vascular origin.3 Multiple treatments are proposed
in the dermatologic literature for ALHE. We report a
case of multiple lesions on the neck treated with
low-dose methotrexate.CASE REPORT
A 31-year-old woman presented in 2006 with a
single erythematous nodule with overlying fine
scales located on the right side of the neck. Three
months later, she returned to the clinic with
additional new lesions on the same side of the
neck. Ultrasound scan and cutaneous magnetic
resonance imaging showed proliferation of
subcutaneous blood vessels without arteriovenous
malformation. The histopathology findings showed
vascular hyperplasia lined by enlarged endothelial
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infiltrate of lymphocytes and eosinophils (Fig 1).2
Peripheral hypereosinophilia (900 g/L) was also
seen. The patient was treated initially with oral
prednisone, 30 mg daily for 1 month, resulting in
complete regression of the lesions. She gained 6 kg
during the treatment period but showed no other
adverse effects. However, despite slowly tapering
the prednisone, the lesions recurred 48 hours after
stopping treatment. Remarkable long-lasting
improvement was observed after initiation of
pulsed dye laser therapy. A total of 6 complete
sessions at a rate of one session per month led to
resolution of symptoms for 6 years. After 6 years,JAAD Case Reports 2015;1:342-4.
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Fig 2. Multiple well-infiltrated, brown-violaceous plaques and nodules on the neck before
initiation of the methotrexate (A). Twelve months after treatment with methotrexate, the lesions
regressed dramatically. There remains scars of the initial biopsies with postinflammatory
hyperpigmentation and some minimally inflamed macular lesions (B).
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sessions of pulsed dye laser therapy (Fig 2, A). The
patient refused to take systemic steroids because of
their adverse side effects. While reviewing the
dermatologic literature, we found a case of orbital
ALHE resistant to corticosteroid therapy in which
the patient was treated successfully with low-dose
methotrexate and remained symptom free 1 year
after discontinuation of the treatment.4 After an
extensive discussion of the different treatment
modalities and their potential risks and benefits
with our patient, we opted for the initiation of
methotrexate. The patient was started on metho-
trexate, 15 mg/wk for 12 months, after which we
observed that the lesions were significantly
improved (Fig 2, B). The dose was subsequently
reduced to 10 mg/wk for 7 months and then to
5 mg/wk for 3 months, after which methotrexate
was stopped. The patient remained free of recur-
rence with a 4-month follow-up.DISCUSSION
Treatment is usually required for ALHE, as
spontaneous regression is rare. Many treatments
are proposed in the dermatologic literature.
Complete surgical excision is the preferred choice,
but recurrencemay happen if excision is incomplete.
Other alternative treatments have been reported
with variable levels of success. These treatments
include laser therapy (pulsed dye, CO2, copper
vapor),5,6 systemic or intralesional corticosteroid
injection,7 cryotherapy, imiquimod, tacrolimus,
isotretinoin, radiotherapy, interferon alfa 2a, antie
interleukin-5 antibody, photodynamic therapy, and
methotrexate.4
The surgical excision was not applicable in our
case because of the multiplicity and the infiltrativenature of the lesions. This infiltrative nature could
also explain the inefficacy of laser therapy at this
stage.
Methotrexate is a potent competitive antagonist
of the enzyme dihydrofolate reductase that is essential
in DNA synthesis process. Methotrexate has anti-
inflammatory, immunosuppressive, and antiprolifer-
ative effects and has been used successfully in the
treatment of various skin diseases either with or
without a vascular component. Examples of these
cutaneous lesions with vascular components include
various vasculitides such as polyarteritis nodosa,
Takayasu arteritis, and Wegener granulomatosis.8
The advantages of methotrexate include the
once-weekly administration, the well-established
side-effect profile, and the low cost.
The treatment regimen was well tolerated in our
case, and the patient had a positive response. This
response can be attributed to methotrexate’s dual
mechanism of action: anti-inflammatory and
antiangiogenic. The patient underwent periodic
check-ups with no adverse effects observed either
clinically or from laboratory markers that included
complete blood count with differentiation,
creatinine, and liver transaminases. We continue
following up with her and observing the efficacy of
the treatment. Although there are no studies to
confirm the most effective management regimen,
we believe that methotrexate could have a promising
role in the treatment of ALHE.REFERENCES
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